Steven J Chadban

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2647262/publications.pdf

Version: 2024-02-01

69 papers

4,284 citations

293460 24 h-index 63 g-index

70 all docs

70 docs citations

times ranked

70

7295 citing authors

#	Article	IF	CITATIONS
1	Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 549-560.	2.1	8
2	Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: A systematic review. Transplantation Reviews, 2022, 36, 100652.	1.2	7
3	Statistical analysis plan for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation. Trials, 2022, 23, 52.	0.7	2
4	Dialysis Disequilibrium: Is Acidosis More Important than Urea?. Case Reports in Nephrology, 2022, 2022, 1-5.	0.2	1
5	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. Journal of the American Society of Nephrology: JASN, 2022, 33, 665-673.	3.0	4
6	Rapidly progressive crescentic diabetic nephropathy: two case reports. Internal Medicine Journal, 2022, 52, 479-484.	0.5	3
7	Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney International, 2022, 101, 1077-1080.	2.6	9
8	The Utility of Pre- and Post-Transplant Oral Glucose Tolerance Tests: Identifying Kidney Transplant Recipients With or at Risk of New Onset Diabetes After Transplant. Transplant International, 2022, 35, 10078.	0.8	4
9	Comparison of the effect of single vs dual antiplatelet agents on post-operative haemorrhage after renal transplantation: A systematic review and meta-analysis. Transplantation Reviews, 2021, 35, 100594.	1.2	2
10	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. Kidney International Reports, 2021, 6, 1513-1524.	0.4	5
11	MO518INSIDE CKD: MODELLING THE ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE IN THE AMERICAS AND THE ASIA-PACIFIC REGION USING PATIENT-LEVEL MICROSIMULATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
12	Global Perspective on Kidney Transplantation: Australia. Kidney360, 2021, 2, 1641-1644.	0.9	8
13	Young adult onset type 2 diabetes versus type 1 diabetes: Progression to and survival on renal replacement therapy. Journal of Diabetes and Its Complications, 2021, 35, 108023.	1.2	7
14	The "New Caledonia COVID-19 Paradox― Dramatic Indirect Impact of the Pandemic on Organ Donation and Transplantation in a Nonprevalence Country. Kidney International Reports, 2021, 6, 2519-2520.	0.4	0
15	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
16	Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis. American Journal of Kidney Diseases, 2020, 75, 693-704.	2.1	14
17	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	0.5	172
18	Development and outcomes of de novo donorâ€specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. American Journal of Transplantation, 2020, 20, 1351-1364.	2.6	19

#	Article	IF	Citations
19	Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?. Cancer Reports, 2020, 3, e1250.	0.6	9
20	Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. Annals of Internal Medicine, 2020, 173, 426-435.	2.0	144
21	Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. Journal of the American Society of Nephrology: JASN, 2020, 31, 2887-2899.	3.0	92
22	Significant impact of COVID-19 on organ donation and transplantation in a low-prevalence country: Australia. Kidney International, 2020, 98, 1616-1618.	2.6	17
23	Health-Related Quality of Life in People Across the Spectrum of CKD. Kidney International Reports, 2020, 5, 2264-2274.	0.4	25
24	Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid–Mediated Activation of G Protein–Coupled Receptors GPR43 and GPR109A. Journal of the American Society of Nephrology: JASN, 2020, 31, 1267-1281.	3.0	153
25	Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation, Trials, 2020, 21, 428.	0.7	16
26	Prevalence of chronic kidney disease in obesity hypoventilation syndrome and obstructive sleep apnoea with severe obesity. Sleep Medicine, 2020, 74, 73-77.	0.8	2
27	Deceased Donor Kidney Transplantation in New Caledonia: A Unique Collaboration With Australia. Transplantation, 2020, 104, 1-3.	0.5	9
28	Suspension and resumption of kidney transplant programmes during the COVID \hat{a} pandemic: perspectives from patients, caregivers and potential living donors \hat{a} a qualitative study. Transplant International, 2020, 33, 1481-1490.	0.8	21
29	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, 708-714.	0.5	73
30	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, S11-S103.	0.5	306
31	Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SFâ€6D utility and mental component SFâ€36 quality of life: An AusDiab analysis. Nephrology, 2019, 24, 605-614.	0.7	10
32	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplantation Reviews, 2019, 33, 191-199.	1.2	12
33	Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplantation Direct, 2019, 5, e416.	0.8	56
34	One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study). Journal of the American Society of Nephrology: JASN, 2019, 30, 1061-1072.	3.0	19
35	Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. Transplantation, 2019, 103, 1705-1713.	0.5	4
36	Interleukin 17A promotes diabetic kidney injury. Scientific Reports, 2019, 9, 2264.	1.6	46

#	Article	IF	CITATIONS
37	Authors' Reply. Journal of the American Society of Nephrology: JASN, 2019, 30, 2276-2277.	3.0	2
38	Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study. Journal of Alzheimer's Disease, 2019, 70, S19-S30.	1.2	17
39	Evolution of Glycemic Control and Variability After Kidney Transplant. Transplantation, 2018, 102, 1563-1568.	0.5	16
40	Preexisting Cancer in Transplant Candidates. Transplantation, 2018, 102, 1037-1038.	0.5	3
41	Novel TOF-MS Means of Quantifying ApoAl Amyloid Protein Load After Combined Liver Kidney Transplantation. Transplantation, 2018, 102, e192-e193.	0.5	0
42	The Treatment of Antibody-Mediated Rejection in Kidney Transplantation. Transplantation, 2018, 102, 557-568.	0.5	128
43	Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression. BMC Nephrology, 2018, 19, 55.	0.8	20
44	Highâ€dose intravenous methotrexate with highâ€flux, extendedâ€hours haemodialysis in treatment of primary central nervous system, postâ€transplant lymphoproliferative disorder and endâ€stage kidney disease: A case report. Nephrology, 2018, 23, 1063-1064.	0.7	5
45	De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. American Journal of Transplantation, 2018, 18, 2977-2986.	2.6	15
46	Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice. Scientific Reports, 2018, 8, 8319.	1.6	40
47	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	3.0	193
48	Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease : A mixedâ€methods study. Nephrology, 2017, 22, 374-381.	0.7	18
49	The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney International, 2017, 91, 954-963.	2.6	44
50	Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes and Endocrinology, the, 2017, 5, 26-33.	5.5	57
51	Improving Our Understanding of Quality of Life in CKD. American Journal of Kidney Diseases, 2016, 67, 820-821.	2.1	7
52	Josette Marie Eris April 7, 1959 to April 6, 2016 TTS Councilor and Professor. Transplantation, 2016, 100, 1596.	0.5	0
53	Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms. Journal of the American Society of Nephrology: JASN, 2016, 27, 1272-1275.	3.0	5
54	Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Troms \tilde{A}_s study. Nutrition Journal, 2015, 14, 49.	1.5	47

#	Article	IF	CITATIONS
55	Pregnancy Outcomes for Kidney Transplant Recipients With Transplantation as a Child. JAMA Pediatrics, 2015, 169, e143626.	3.3	20
56	TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PLoS ONE, 2014, 9, e97985.	1.1	111
57	Is it time to increase access to transplantation for those with diabetic end-stage kidney disease?. Kidney International, 2014, 86, 464-466.	2.6	4
58	Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. JAMA - Journal of the American Medical Association, 2014, 311, 2518.	3.8	760
59	Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia–reperfusion injury in mice. Kidney International, 2014, 85, 824-832.	2.6	56
60	Macrophages in renal transplantation: Roles and therapeutic implications. Cellular Immunology, 2014, 291, 58-64.	1.4	15
61	The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. PLoS ONE, 2014, 9, e108844.	1.1	91
62	Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. International Journal of Clinical and Experimental Pathology, 2014, 7, 481-95.	0.5	21
63	The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. American Journal of Physiology - Renal Physiology, 2013, 305, F143-F154.	1.3	106
64	KHAâ€CARI guideline: KHAâ€CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Nephrology, 2012, 17, 204-214.	0.7	56
65	HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2010, 21, 1878-1890.	3.0	315
66	Macrophages and Kidney Transplantation. Seminars in Nephrology, 2010, 30, 278-289.	0.6	31
67	Immunosuppression in renal transplantation: some aspects for the modern era. Transplantation Reviews, 2008, 22, 241-251.	1.2	19
68	TLR4 activation mediates kidney ischemia/reperfusion injury. Journal of Clinical Investigation, 2007, 117, 2847-2859.	3.9	720
69	Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. American Journal of Kidney Diseases, 2007, 49, 301-309.	2.1	62